Navigation Links
Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
Date:5/31/2008

any dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation statements related to the future development and potential efficacy of XL765 and the timing of the initiation of clinical trials for XL765. Words such as "plan," "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current plans, assumptions, beliefs and expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward- looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the potential failure of XL765 to demonstrate safety and efficacy in clinical testing, our ability to initiate and complete pivotal trials for XL765 at the referenced times; the timing and level of expenses associated with the growth of proprietary programs and other collaborations; the therapeutic and commercial value of XL765 and our other compounds; our relationship with our partners; and our ability to enter into new collaborations, continue existing co
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
9. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
10. Exelixis Announces First Quarter 2008 Financial Results
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... -- Dr. Davis Lee , CMIO for PIH ... the 2013 AMDIS Award, a prestigious recognition saluting excellence ... "On behalf of Allscripts, I,d like to congratulate ... continuous efforts to improve patient care and population health," ... Executive Officer of Allscripts. "We are committed to our ...
(Date:6/19/2013)... 19, 2013 The American Association for Homecare (AAHomecare), ... Maryland , announced today the filing of a ... D.C. , asking that the scheduled July 1 expansion ... equipment (DME) be stopped because of serious licensing irregularities. ... Services (HHS) Secretary Kathleen Sebelius as the ...
(Date:6/19/2013)... THOUSAND OAKS, Calif. , June 19, 2013 ... the United States , Canada ... are this year,s recipients of the Amgen Award for Science ... recognizes extraordinary teachers at the kindergarten through 12th grade level ... results in science education. With a long-standing commitment ...
Breaking Medicine Technology:Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 2Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 3Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 4Allscripts Congratulates Dr. Davis Lee, Winner of the 2013 Association of Medical Directors of Information Systems (AMDIS) Award 5AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 2AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 3AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 4AAHomecare and Maryland DME Provider Take Medicare Agency to Court Over Competitive Bidding Program 5Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 2Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 3
... 17, 2011 Surgical Information Systems ("SIS") announced ... information management systems as a key component of ... the Healthcare Information and Management Systems Society, February ... industry presentations and solution demonstrations, SIS will showcase ...
... Therapeutics, Inc., a developer of novel lumbar spine anulus ... first patient, December 17, 2010, in a Randomized Clinical ... prevent reherniations following lumbar discectomy, while allowing the surgeon ... possible preserving normal disc height and biomechanics. Barricaid accomplishes ...
Cached Medicine Technology:Surgical Information Systems Focuses on Surgery and Anesthesia as a Key Component of the EHR at HIMSS11 2Surgical Information Systems Focuses on Surgery and Anesthesia as a Key Component of the EHR at HIMSS11 3Intrinsic Enrolls First Patient in Barricaid® Trial 2
(Date:6/20/2013)... Millions of Britons are risking ... because they do not brush their teeth every day, ... , Seven million Britons do not clean their teeth ... latest data from the British Dental Health Foundation shows. ... the BDHF also admitted that they forgot to floss ...
(Date:6/20/2013)... In an article found on Science ... can show similarities between an addiction to drugs, and ... current global obesity pandemic. , To test the hypothesis ... one can be addicted to drugs, Dr Francesco Leri, ... the University of Guelph, has studied the effects of ...
(Date:6/20/2013)... 20, 2013 Creighton University ... Service Honor Roll – the highest federal recognition a ... volunteering, student- service learning and civic engagement as well ... the Corporation for National and Community Service, is given ... Creighton. “Our foundation at Creighton is based on spiritual ...
(Date:6/19/2013)... (PRWEB) June 20, 2013 Everyone is looking for ... and inexpensive way to do so. It is called Skin ... - only 5 minutes per day - to improve health and ... improves general health. How? , Skin Brushing improves general health ... it aids the lymphatic system to drain toxins , ...
(Date:6/19/2013)... (PRWEB) June 20, 2013 Shreya Rangarajan ... the global youth summit on the future of medicine. ... to the Global Youth Summit on the Future of ... Park Country School and the state of Maryland at ... providers will practice in an environment hard to imagine ...
Breaking Medicine News(10 mins):Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 2Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 3Health News:Research Suggests That Unhealthy Food Addiction Could Explain Global Obesity Epidemic 2Health News:Creighton Again Named to President’s Honor Roll - University Picks Up Sixth Recognition Award for Service 2Health News:Creighton Again Named to President’s Honor Roll - University Picks Up Sixth Recognition Award for Service 3Health News:A Fast and Fun Way to Better Skin Quality and Overall Health, says Sublime Beauty® 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 3
... the U.S. Food,and Drug Administration (FDA) approved Abbott,s TRILIPIX(TM) ... help lower triglycerides,and LDL cholesterol, and to raise HDL ... first and only fibrate to be approved for use ... guidelines,recommend the combination of a fibrate with a statin ...
... 15 Two leading cancer physicians and,researchers affiliated with ... Antonio Breast Cancer Symposium. Three others presented their,research in ... 14. , Dr. ... its breast,cancer research committee, presented findings on the largest ...
... role in immune, inflammatory processes, study says , , ... have higher levels of the obesity-related hormone leptin than ... study included 77 psoriasis patients and a control group ... researchers gathered health information about the participants and analyzed ...
... to Controlling Costs, Improving Quality as Health Care Reform Debate Centers ... WASHINGTON, Dec. 15 House Ways and Means Health Subcommittee Chairman ... senior counsel to Sen. Max Baucus, will join health care expert ... America,s Future co-director Roger Hickey on a conference call ...
... first piece of DNA luxury jewellery will be sold,at ... be used to finance the,anti-aging services and life extension ... Dr. Ivan de Weber, a ... co-founder of both Inneova(TM) and DNArtistic has,brought together a ...
... High School Student Volunteers Collaborate in Musical Production , ... HAWTHORNE, N.J., Dec. 15 Sharing The ... organization and conservatory bringing together individuals with mild to ... to announce that its members, all children and teens ...
Cached Medicine News:Health News:Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 2Health News:Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 3Health News:Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 4Health News:US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium 2Health News:US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium 3Health News:US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium 4Health News:Obesity-Related Hormone Tied to Psoriasis 2Health News:DNA Jewel to Finance Anti-Aging Services & Cancer Research 2Health News:Sharing The Arts & Ridgewood High School Present Musical Production of Charlie and The Chocolate Factory 2
Key periosteal elevators, blade width 1" (25 mm), total length 7 1/2" (191 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Cushing periosteal elevators, Gutsch handle, sharp, narrow, blade width 3/16" (5 mm), length 7 5/8" (194 mm)....
Cushing Little Joker periosteal elevators, solid handle, blade width 1/4" (6 mm), length 7 1/2" (191 mm)....
Medicine Products: